Deshpande N, Mitchell I P, Hayward S W, Love S, Towler J M
Imperial Cancer Research Fund, Lincoln's Inn Fields, London.
J Urol. 1991 Nov;146(5):1247-51. doi: 10.1016/s0022-5347(17)38060-6.
The activities of 6 enzymes of carbohydrate metabolism were estimated in superficial transitional cell carcinomas from 103 patients undergoing transurethral resection of the bladder for the first time. The patients were followed by quarterly endoscopic examinations for a maximum of 81 months (median 33 months). During followup 24 patients had progressive disease. The activities of phosphofructokinase and phosphohexose isomerase were significantly lower in tumors from patients whose disease had superficially invaded the lamina propria (stage pT1) than in others in whom it was confined to the bladder mucosa (stage pTa). Similarly the activities of the 2 enzymes were significantly higher in well differentiated (grade 1) than in moderately well differentiated (grade 2) carcinomas. Univariate analyses using the log rank test showed that neither pathological stage nor malignancy grade of the carcinoma was a significant factor in predicting the risk of progression. Of the 6 enzymes, below median activities of phosphofructokinase, lactate dehydrogenase and phosphohexose isomerase were associated with a significantly increased risk of progression in these patients. Multivariate analyses using Cox's proportional hazards model showed that the activity of lactic dehydrogenase in superficial transitional cell carcinoma is an independent prognostic factor in predicting the risk of progression. It is postulated that the measurements of the activities of the 3 enzymes in tumors from patients with superficial transitional cell carcinoma might help to select individual patients with a high risk of progression for adjuvant intravesical treatments.
对103例首次接受经尿道膀胱切除术的浅表性移行细胞癌患者的碳水化合物代谢6种酶的活性进行了评估。对患者每季度进行一次内镜检查,随访时间最长为81个月(中位时间33个月)。随访期间,24例患者出现疾病进展。疾病已侵犯固有层(pT1期)患者的肿瘤中磷酸果糖激酶和磷酸己糖异构酶的活性显著低于疾病局限于膀胱黏膜(pTa期)的其他患者。同样,这两种酶在高分化(1级)癌中的活性明显高于中分化(2级)癌。使用对数秩检验的单因素分析表明,癌的病理分期和恶性程度均不是预测进展风险的显著因素。在这6种酶中,磷酸果糖激酶、乳酸脱氢酶和磷酸己糖异构酶活性低于中位数与这些患者进展风险显著增加相关。使用Cox比例风险模型的多因素分析表明,浅表性移行细胞癌中乳酸脱氢酶的活性是预测进展风险的独立预后因素。据推测,测量浅表性移行细胞癌患者肿瘤中这3种酶的活性可能有助于选择进展风险高的个体患者进行辅助膀胱内治疗。